Press Releases and News

October 17 2018

Landos Biopharma at BIO Investor Forum

​ Landos Biopharma to Participate at BIO Investor Forum BLACKSBURG, VIRGINIA, October 17, 2018 – Landos Biopharma, a clinical-stage biopharmaceutical company focused[...]

July 12 2018

First Human Dosing of BT-11 Announced

Landos Biopharma Initiates Phase 1 Clinical Trial of BT-11, an Oral LANCL2 Agonist for Treatment of IBD BLACKSBURG, VA, July 12, 2018 – Landos Biopharma, Inc., a clinical-stage[...]

June 05 2018

New Data from Landos Biopharma

Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018 BLACKSBURG, VA and WASHINGTON, DC June 5, 2018 – Landos[...]